ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease | MicrobiomeTrials← Back to trialsNCT07718659
ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-12-01Est. Completion: 2029-12-01
Enrollment target: 8 participants Locations- The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China
Other microbiome trials you might be interested in
Idiopathic Parkinson´s DiseaseParkinson's Disease
This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be i…
Tucson, United StatesEst. completion Sep 2027
Parkinson Disease
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study …
Birmingham, United StatesEst. completion Dec 2033
Recruiting
Parkinson DiseaseProgressive Supranuclear Palsy
To perform a prospective cohort study with \[(18)F\]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year …
Ann Arbor, United StatesEst. completion Jun 30, 2027